MARKET

GKOS

GKOS

Glaukos Corp
NYSE
245.72
-0.31
-0.13%
After Hours: 245.72 0 0.00% 17:23 11/13 EST
OPEN
246.20
PREV CLOSE
246.03
HIGH
249.07
LOW
242.34
VOLUME
546.37K
TURNOVER
--
52 WEEK HIGH
255.19
52 WEEK LOW
83.78
MARKET CAP
14.55B
P/E (TTM)
-83.4533
1D
5D
1M
3M
1Y
5Y
1D
Glaukos (GKOS) Stock May Be 33% Undervalued As It Joins A New Index
Simply Wall St · 12h ago
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
NASDAQ · 1d ago
Glaukos (GKOS) Jumped, What Is Behind The Fresh Attention?
Simply Wall St · 4d ago
Weekly Report: what happened at GKOS last week (1102-1106)?
Weekly Report · 4d ago
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Benzinga · 5d ago
Learn Why The Bull Case For Glaukos Stock Could Change Following S&P 400 Inclusion
Simply Wall St · 6d ago
Glaukos Corporation Outlines Product Roadmap and Commercial Updates in November 2026 Investor Presentation
NASDAQ · 11/06 16:31
Glaukos Highlights Procedural and Sustained-Release Eye Therapies
TipRanks · 11/06 12:30
More
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.

Webull offers Glaukos Corp stock information, including NYSE: GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.